Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib with Gemcitabine/nab-Paclitaxel in Advanced Pancreatic Cancer
NCT02902484Phase 2Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Sep 2017
- Primary completion
- Oct 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in pancreatic adenocarcinoma (PDAC), sponsored by UT Southwestern Medical Center. Started Sep 2017; status: terminated.
02
Drugs
nintedanib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02902484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02902484.